Merck ( Merck )


Merck's picture

Merck Press Release and News

Merck press release, blog etc

07/02/2018 - 04:58 LYNPARZA (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer
07/02/2018 - 04:46 Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018
06/26/2018 - 21:06 Merck Announces Findings from WHO-led Study of Investigational Heat-Stable Carbetocin for Preventing Excessive Bleeding After Childbirth
06/26/2018 - 21:00 Merck to Hold Second-Quarter 2018 Sales and Earnings Conference Call on July 27
06/26/2018 - 19:45 LYNPARZA (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
06/22/2018 - 19:09 Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA (sitagliptin)
06/18/2018 - 11:57 Late-Breaking Data to be Presented from the Comparative Trials with Sitagliptin (CompoSIT) Program on the Continuation of JANUVIA (sitagliptin) Treatment Among Patients Initiating Insulin Therapy
06/13/2018 - 10:04 FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) for GARDASIL9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
05/31/2018 - 11:19 Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection
05/24/2018 - 19:26 Eisai and Merck Provide Update on Supplemental New Drug Application (Snda) for Lenvatinib in First-line Unresectable Hepatocellular Carcinoma
04/22/2018 - 02:43 Pivotal Phase 3 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Demonstrated Favorable Overall Response Against Certain ImipenemNon-Susceptible Bacterial Infections
04/17/2018 - 06:12 Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
04/17/2018 - 05:51 Merck Advances Clean Energy Goals with Invenergy
04/14/2018 - 23:56 Updated Overall Survival Data for LYNPARZA (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR
04/03/2018 - 04:25 The European Medicines Agency Accepts Regulatory Submission for LYNPARZA (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
04/02/2018 - 10:51 Merck Receives 2018 ENERGY STAR Sustained Excellence Award
04/02/2018 - 06:05 Merck to Hold First-Quarter 2018 Sales and Earnings Conference Call on May 1
03/20/2018 - 22:45 MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO Plus (fluralaner plus moxidectin) Spot-on Solution for Cats